Wedbush Reaffirms "Outperform" Rating for Perspective Therapeutics (NYSE:CATX)

Key Points

• Wedbush has reiterated an "outperform" rating for Perspective Therapeutics (NYSE:CATX) with a target price of $11.00, indicating a potential upside of 218.56% from its last closing price.
• Other analysts have also shown positive sentiment, with Lifesci Capital giving a "strong-buy" rating and B. Riley raising their target price to $12.00, showing strong confidence in the stock.
• Currently, 54.66% of Perspective Therapeutics' stock is owned by institutional investors, highlighting significant investment interest in the company.

Perspective Therapeutics (NYSE:CATX - Get Free Report)'s stock had its "outperform" rating reiterated by Wedbush in a research note issued on Thursday,RTT News reports. They presently have a $11.00 target price on the stock. Wedbush's price target would suggest a potential upside of 218.56% from the stock's previous close.

CATX has been the topic of several other research reports. Lifesci Capital raised shares of Perspective Therapeutics to a "strong-buy" rating in a research note on Saturday, July 12th. B. Riley reaffirmed a "buy" rating and issued a $12.00 price target (up previously from $9.00) on shares of Perspective Therapeutics in a research note on Monday, June 23rd. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $10.00 price target on shares of Perspective Therapeutics in a research note on Friday, September 19th. Three research analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of "Buy" and an average price target of $12.56.

Perspective Therapeutics Trading Up 0.7%

Shares of CATX traded up $0.02 during midday trading on Thursday, hitting $3.45. The stock had a trading volume of 110,802 shares, compared to its average volume of 909,675. Perspective Therapeutics has a 1 year low of $1.60 and a 1 year high of $13.56. The stock's 50 day moving average is $3.55 and its 200 day moving average is $3.07.

Institutional Trading of Perspective Therapeutics

A number of institutional investors have recently modified their holdings of CATX. ProShare Advisors LLC boosted its holdings in shares of Perspective Therapeutics by 49.1% in the 4th quarter. ProShare Advisors LLC now owns 15,225 shares of the company's stock valued at $49,000 after buying an additional 5,011 shares in the last quarter. Two Sigma Advisers LP bought a new stake in shares of Perspective Therapeutics in the 4th quarter valued at about $484,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in Perspective Therapeutics by 19.6% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 70,150 shares of the company's stock worth $224,000 after purchasing an additional 11,472 shares in the last quarter. Bank of New York Mellon Corp boosted its stake in Perspective Therapeutics by 11.1% in the 1st quarter. Bank of New York Mellon Corp now owns 159,366 shares of the company's stock worth $339,000 after purchasing an additional 15,897 shares in the last quarter. Finally, Federated Hermes Inc. acquired a new stake in Perspective Therapeutics in the 1st quarter worth approximately $288,000. 54.66% of the stock is currently owned by institutional investors.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.